Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Immunomedics reports phase II results of CEA-Cide as colorectal cancer therapy

June 7, 2000

Progenics to continue GMK cancer vaccine trial as an extension study

June 2, 2000

CPMP recommends approval of Herceptin for treatment of metastatic breast cancer

May 29, 2000

Single doses of HspE7 are well tolerated and elicit specific cell-mediated immunity

May 29, 2000

New fusion toxin with therapeutic potential in acute-phase CML presented at ASCO

May 29, 2000

Phase I trial of Hu1D10 continues following positive results in first lymphoma patients treated

May 29, 2000

Antisoma temporarily halts Theragyn phase III enrollment

May 29, 2000

News from ASCO: Medarex's MDX-210 may be useful in breast cancer and ovarian cancer

May 26, 2000

Vaccination with ras peptides as therapeutic strategy in pancreatic cancer

May 26, 2000

Cell Genesys reports encouraging preclinical data for leukemia vaccine

May 25, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...